Increase in the level of proinflammatory cytokine hmgb1 in nasal fluids of patients with rhinitis and its sequestration by glycyrrhizin induces eosinophil cell death by Cavone, Leonardo et al.
123
Copyright © 2015 by Korean Society of Otorhinolaryngology-Head and Neck Surgery.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Clinical and Experimental Otorhinolaryngology    Vol. 8, No. 2: 123-128, June 2015 http://dx.doi.org/10.3342/ceo.2015.8.2.123
Original Article
INTRODUCTION
High mobility group protein box 1 (HMGB1) is a protein present 
in the nucleus of all cells, and it plays a key role in maintenance 
of nuclear homeostasis. HMGB1 is organized into three different 
regions including two DNA binding domains called box A and B, 
and an acidic C-terminal tail. Besides box A and B, two nuclear 
localization signals are present in the protein structure at amino 
acids 28–44 and 179–185. The protein binds to the minor groove 
of linear DNA, and bends the double helix up to 90° or more, 
thereby altering chromatin architecture and allowing recruitment 
of transcription-regulating factors [1]. Numerous lines of evidence 
point to HMGB1 as a key regulator of enhanceosome organiza-
tion, transcription factor recruitment, and overall activation of the 
basal transcriptional machinery [1,2]. 
 • Received July 3, 2013  
Revised August 29, 2013 
Accepted November 7, 2013 
 • Corresponding author: Leonardo Cavone 
Department of Health Sciences, Section of Clinical Pharmacology and 
Oncology, University of Florence, Viale Pieraccini 6, 50139 Firenze, Italy 
Tel: +39-55-427-1229, Fax: +39-55-427-1280 
E-mail: leonardo.cavone@unifi.it
pISSN 1976-8710   eISSN 2005-0720
Increase in the Level of Proinflammatory Cytokine 
HMGB1 in Nasal Fluids of Patients With Rhinitis 
and its Sequestration by Glycyrrhizin Induces 
Eosinophil Cell Death
Leonardo Cavone1·Caterina Cuppari2·Sara Manti2·Luisa Grasso2·Teresa Arrigo2·Luca Calamai1·Carmelo Salpietro2 
Alberto Chiarugi1
1Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Firenze;  
2Department of Pediatrics, Unit of Genetic and Immunology, University of Messina, Messina, Italy
Objectives. The nuclear protein high mobility group protein box 1 (HMGB1) is a proinflammatory mediator that belongs 
to the alarmin family of proinflammatory mediators, and it has recently emerged as a key player in different acute 
and chronic immune disorders. Several lines of evidence demonstrate that HMGB1 is actively released extracellularly 
from immune cells or passively released from necrotic cells. Because of the ability of HMGB1 to sustain chronic in-
flammation, we investigated whether the protein is present in nasal fluids of patients with different forms of rhinitis. 
Methods. HMGB1 levels were evaluated in nasal fluids of healthy subjects or rhinitis patients who were treated or not 
treated with different treatments. 
Results. We report that the level of HMGB1 was significantly increased in nasal fluids of patients with allergic rhinitis, pa-
tients with NARES (nonallergic rhinitis with eosinophiliac syndrome), as well as patients with polyps. We also found 
that a formulation containing the HMGB1-binding compound glycyrrhizin (GLT) reduced the HMGB1 content in 
nasal fluids of rhinitis patients to an extent similar to that with nasal budesonide treatment. We also found that 
among the cultured human leukocyte populations, eosinophils released higher amounts of HMGB1. Based on the 
ability of HMGB1 to sustain eosinophil survival and the ability of GLT to inactivate HMGB1, we report that GLT se-
lectively killed cultured eosinophils and had no effect on neutrophils, macrophages, and lymphocytes. 
Conclusion. Collectively, these data underscore the role of HMGB1 in rhinitis pathogenesis and the therapeutic potential 
of GLT formulations in treatment of chronic inflammatory disorders of the nasal mucosa.
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 Surprisingly, a large body of experimental evidence demon-
strates that HMGB1 is also endowed with extracellular signaling 
functions on various cell types, including those of the immune 
system [3-5]. The protein has been recently included into the 
“alarmin” family, a term identifying a group of endogenous fac-
tors, also known as “endokines,” which once released in the ex-
tracellular space interact with membrane receptors on immune 
cells to activate the inflammatory response [6]. Of note, HMGB1 
can be released from the nucleus to the extracellular milieu in 
response to different stimuli. While necrotic cells passively release 
the protein following nuclear and plasma membrane rupture, cells 
undergoing apoptosis retain HMGB1 into the nucleus strongly as-
sociated with condensed chromatin. Besides passive release during 
necrosis, HMGB1 can be actively secreted by several cell types [7]. 
Among these, activated immune cells constitute a major source of 
extracellular HMGB1 in inflamed tissues [8]. 
 Once released, HMGB1 induces proliferation, cell migration 
and survival, as well as inflammation. HMGB1 behaves as a pro-
totypical cytokine once extracellularly released and plays an im-
portant role in development and maintenance of the inflammato-
ry response. However, it is worth noting that HMGB1 release oc-
curs considerably later than secretion of other classical proinflam-
matory mediators (tumor necrosis factor-α, interleukin-1β), indi-
cating that the protein is a delayed mediator of inflammation [9]. 
 In light of its remarkable pathogenetic relevance, great effort 
has been focused on counteracting the proinflammatory effects 
of HMGB1. Although different strategies have been proposed at 
the preclinical level, almost none of them have reached clinical 
application [3]. A notable exception is glycyrrhizin (GLT), an al-
kaloid extracted from Glycyrrhiza Glabra used in Japan as a 
remedy to treat different inflammatory disorders including hepa-
titis. Recent findings demonstrate that GLT binds to a specific 
pocket of HMGB1, thereby precluding the protein’s ability to 
bind to its cognate receptors and to exert proinflammatory and 
chemotactic effects [10]. Different formulations containing GLT 
have therefore been proposed as therapeutic tools for treatment 
of disorders whose pathogenesis is postulated to be prompted 
and/or sustained by HMGB1. 
 As for the potential pathogenetic role of HMGB1 in the respi-
ratory tract, very recent studies have shown increased levels of 
the protein in patients affected by asthma [11]. However, it is 
not known whether HMGB1 plays a role in inflammatory pro-
cesses of the upper respiratory tract such as those during rhinitis 
or nasal polyps. In the present study, we therefore evaluated the 
HMGB1 levels in nasal fluids of patients with different forms of 
rhinitis. Given that HMGB1 plays a key role in promoting sur-
vival of eosinophils, leukocytes with key pathogenetic roles in 
allergic and nonallergic immune disorders of the nasal mucosa, 
we also checked whether GLT affects the survival of different 
human leukocytes including eosinophils.
 
MATERIALS AND METHODS
Subjects and experimental design
This study included children with allergic rhinitis (AR) recruited 
by family paediatricians of Messina. The nasal HMGB1 concen-
tration was measured in the laboratory of Unit of Genetics and 
Paediatric Immunology of the Policlinico of Messina. All partici-
pating subjects were of Italian origin.
 The details of the study were explained to the parents/guard-
ians of the children who were participating in the study, and writ-
ten informed consent was obtained from each parent/guardian. A 
physician performed the physical examination of each child. De-
mographic data and other clinical characteristics of the study sub-
jects were collected using the questionnaires. AR was diagnosed 
according to the presence of typical nasal symptoms (nasal itch-
ing, sneezing, watery rhinorrhea, and nasal obstruction) and sen-
sitization to pollen allergen, documented by a positive skin prick 
test (SPT). Inclusion criteria were: age of between 6 and 16 years, 
a diagnosis of AR, sensitization to Parietaria pollen, and the pres-
ence of nasal symptoms.
 Exclusion criteria were: perennial AR, any respiratory tract in-
fection within 1 month before the start of the study, other nasal 
disease (including structural abnormalities, nasal polyposis and 
clinically relevant septum deviation), asthma comorbidity (ex-
cluded by history and physical examination), and any treatment 
in the previous month capable of interfering with the results. The 
study was carried out from March 2013 to May 2013, the time 
during which the subjects were naturally exposed to pollens. The 
study was conducted on 170 AR subjects (87 males and 83 fe-
males; median age, 10.3±3.4 years). All children presented with: 
nasal obstruction, nasal itching, sneezing and watery rhinorrhea, 
an increased level of total serum IgE and positive results for the 
Parietaria pollen SPT.
 In accordance with the study protocol, patients were divided 
into three groups; one group received 1 puff of saline (29 males 
and 28 females), one group received 1 puff of Budesonide (32 
males and 25 females) and one group received 1 puff of Narivent 
(DMG, Rome, Italy) (30 males and 26 females) into each nostril 
2 times a day for 1 week. HMGB1 levels in nasal fluids were 
evaluated before and after treatment.
Nasal fluid collection procedure
All subjects underwent nasal lavage as described by Salpietro et 
al. [12]. Briefly, healthy controls and patients affected by different 
types of rhinitis or nasal polyps as well as AR patients before and 
after 1 week of treatment with saline, Narivent or Budesonide 
were placed in a sitting position with the head slightly tilted. Na-
sal lavage was performed with a pipette, by injecting 1.5 mL of 
saline solution (0.9% NaCl at 37°C) into the nostril of the pa-
tient, after closing the possible escape route represented by the 
other nostril with a patch. The recovered liquid was collected after 
a few seconds with the same pipette. Sampling was performed for 
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both nostrils. The fluid was stored at –20°C until HMGB1 mea-
surement. The recovery volume was on average more than 90% 
after nasal lavage.
HMGB1 measurement
HMGB1 concentration was measured in the nasal fluid collected 
from each patient (as described above) by performing an enzyme-
linked immunosorbent assay (ELISA) using an HMGB1 ELISA 
Kit II developed by Shino-Test Corporation (IBL International 
GmbH, Hamburg, Germany) following the manufacturer’s in-
structions. Briefly, samples were diluted 1:5 with sample diluent 
and added to microtiter plates, which were then incubated for 24 
hours at 37°C. After washing, 100 μL/well of antihuman HMGB1 
peroxidase-conjugated monoclonal antibody was added and the 
plates were incubated at room temperature for 2 hours. After ex-
tensive washing, tetramethylbenzidine dihydrochloride was add-
ed to each well. The enzyme reaction was allowed to proceed for 
30 minutes at room temperature. The chromogenic substrate reac-
tion was stopped by adding the stop solution, and the absorbance 
of each well was determined on a microplate reader at 450 nm. 
The HMGB1 concentrations were calculated with reference to a 
standard curve, with a detection limit of 0.2 ng/mL.
Quantitation of GLT and glycyrrhetinic acid
Plasma samples were collected from patients treated with acute 
(1 hour after one puff per nostril) or chronic (after 1 week of 
treatment with 1 puff per nostril twice a day) Narivent adminis-
tration or from healthy subjects 1 hour after consumption of a 
licorice candy (containing 20.5±3 mg of GLT). Samples were 
quantitated by means of liquid cromatography-mass spectometry. 
Briefly, specimens were extracted with methanol and injected in 
a high performance liquid cromatography apparatus consisting of 
a reversed-phase C18 (ODS) column with a mobile phase of 
methanol 1%, formic acid (75:25, vol/vol). Mass spectometry 
determination was performed using negative electrospray ioniza-
tion (negative ESI) in the selected ion monitoring mode. GLT 
was monitored at the m/z 821.1 channel, glycyrrhetinic acid 
(GA) at the m/z 469.2 channel, and internal standard (linuron) 
at the m/z 248.9 channel. The calibration curve was linear over 
the range from 0.05 to 10 μg/mL with a correlation coefficient 
above 0.99.
Leukocyte preparation and cell death evaluation
Blood samples from healthy donors were stratified on a Ficoll 
layer. After centrifugation at 1,500 rpm for 30 minutes at room 
temperature, peripheral blood mononuclear cells were collected 
at the interface with Ficoll and used for preparation of mono-
cytes and lymphocytes as previously described [5]. Cellular pel-
let containing red blood cells and granulocytes was used for 
preparation of eosinophils (isolation kit 130-092010) and neu-
trophils (CD16 microbead 130-045-701) by means of magnetic 
separation procedure using Miltenyi kits following the manufac-
turer’s instructions. Cells were cultured as previously described 
[5]. Cell death was assessed by Propidium iodide labeling and 
cytofluorometric analysis as previously described [13].
RESULTS
Levels of HMGB1 in nasal fluids of patients with rhinitis and 
polyps
We first investigated whether the levels of HMGB1 were altered 
in nasal fluids of patients affected by different forms of rhinitis. 
To this end, we collected nasal fluids from healthy subjects and 
patients affected by AR, non-AR with eosinophilia syndrome 
(NARES) or nasal polyps (12 subjects per group), and evaluated 
their HMGB1 content by means of a commercial ELISA kit (see 
MATERIALS AND METHODS SECTION for further detail). As 
shown in Fig. 1A, we found significant increases in the HMGB1 
content in all the three groups of rhinitis patients. When HMGB1 
levels were compared with those in patients pooled into a single 
group, a 3-fold increase in HMGB1 levels was observed (Fig. 1B). 
The present data showing that the level of proinflammatory cyto-
kine HMGB1 is increased in nasal fluids of patients with different 
forms of rhinitis underscore the therapeutic potential of HMGB1-
inactivating strategies in treatment of inflammatory disorders of 
the nasal mucosa. The nasal formulation Narivent is a GLT-con-
taining medical device used to treat inflammation of the nasal 
mucosa [14]. We therefore compared the efficacy of topical treat-
ments with saline, Narivent, or Budesonide in reducing the 
HMGB1 content in nasal fluids of patients with AR (see MATE-
RIALS AND METHODS SECTION for patient details). As shown 
in Fig. 1C, we found that, at variance with saline, Narivent and 
Budesonide equally reduced the HMGB1 content in nasal fluids 
after 1 week of treatment. Reportedly, GLT is known to inhibit 
11p-hydroxysteroid dehydrogenase 2 and to promote arterial hy-
pertension via cortisol accumulation [15]. However, it is not known 
whether nasal formulations containing GLT can increase cortisol 
levels because of systemic absorption. To address this question, we 
first evaluated the plasma levels of GLT and of its principal metabo-
lite GA in healthy subjects. We found that both acute (i.e., 30 min-
utes after two puffs/nostril, 4.99±0.35 mg GLT/puff) or prolonged 
administration (i.e., two puffs/nostril twice a day per one week) re-
sulted in GLT and GA concentrations in plasma in the order of the 
method detection limit (0.2 ng/mL). Notably, ingestion of a candy 
containing a standard amount of GLT (20.88±3.8 mg) resulted in 
plasma levels (30 minutes after ingestion) that were 2 folds higher 
than those found in patients receiving GLT for one week (Fig. 1D). 
In keeping with the very low plasma concentrations of GLT and 
GA, in subjects receiving Narivent, plasma cortisol levels were not 
different from those in controls (Fig. 1E). Taken together, these find-
ings indicate that nasal treatment with GLT leads to poor systemic 
absorption that is not sufficient to affect the plasma cortisol levels 
and blood pressure, at least in the time window analysed. Data also 
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indicate that ingestion of a single licorice candy is enough to cause 
significantly higher plasma GLT/GA concentrations than those 
in patients treated with nasal GLT formulation for an entire week. 
Release of HMGB1 by different human leukocytes and effects 
of GLT
The identification of increased HMGB1 concentrations in nasal 
fluids of rhinitis patients clearly underscores the pathogenetic 
relevance of this proinflammatory agent in immune disorders of 
the nasal mucosa. It is well known that the latter are frequently 
associated with eosinophilic infiltrates [16,17]. Given the ability 
of HMGB1 to activate and promote survival of eosinophils [18], 
as well as the high levels of the protein in nasal fluids of patients 
with AR and NARES (Fig. 1A) (in which the eosinophilic infiltrate 
is well represented and is of pathogenetic relevance), we next 
planned to evaluate the ability of different leukocytes to release 
HMGB1. Interestingly, we found that among human macrophages 
and granulocytes isolated from peripheral blood of healthy sub-
jects, eosinophils were able to release a higher amount of HMGB1 
within 12 hours of incubation (Fig. 1C). Of note, monocytes, lym-
phocytes, and neutrophils released an amount of HMGB1 (Fig. 
2A) that was almost half of that released by eosinophils. To further 
investigate the ability of the protein to affect half-life of leukocytes 
in culture, we took advantage of the ability of GLT to bind and in-
activate HMGB1. We therefore exposed cultured leukocyte popu-
lations to GLT and evaluated their survival. GLT was used at a 
concentration of 1%, 5 folds lower than that in the anti-inflamma-
tory nasal preparation Narivent. As shown in Fig. 2B, we found 
that GLT selectively killed eosinophils and had no effect on the 
other types of leukocytes.
DISCUSSION
To the best of our knowledge, this is the first evidence to suggest 
that the proinflammatory protein HMGB1 is increased in human 
nasal fluids during inflammatory disorders of the nasal mucosa in 
addition to AR [12]. Notably, NARES patients showed the high-
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Fig. 1. High mobility group protein box 1 (HMGB1)  levels in rhinitis patients, plasma levels of glycyrrhizin, glycyrrhetinic acid (GA), and cortisol 
in patients treated with Narivent (DMG, Rome, Italy) or GLT-containing formulation. (A) HMGB1 content in nasal fluids of healthy subjects and 
patients with different forms of rhinitis/polyps. (B) Comparison of the HMGB1 content in nasal fluids of healthy subjects or subjects affected by 
rhinitis. (C) HMGB1 levels in nasal fluids of patients with allergic rhinitis before and after 1 week of treatment with saline, Narivent, or 
Budesonide. (D) Levels of GLT and GA in subjects treated with acute (i.e., 30 minutes after 1 puff/nostril) or chronic (1 puff/nostril twice a day for 
1 week) Narivent administration, or in subjects 30 minutes after ingestion of a GLT-containing formulation. (E) Plasma cortisol concentrations in 
control subjects or in rhinitis patients who received one week of Narivent treatment (1 puff/nostril twice a day). *P<0.05. **P<0.01. ***P<0.001; 
analysis of variance plus Tukey post hoc test.
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est HMGB1 levels, which was in line with the key proinflamma-
tory role of HMGB1 in eosinophils [18]. As for polyps, we specu-
late that the increased levels of HMGB1 were due to the well-
known inflammatory response that accompanies polyp develop-
ment. Also, in keeping with the different degrees of the inflam-
matory component in different polyps, we found that HMGB1 
levels in nasal fluids from patients with polyps showed highest 
variability (Fig. 1A).
 It is worth noting that the present study, by showing that the 
level of the proinflammatory cytokine HMGB1 is increased in na-
sal fluids of patients with different forms of rhinitis, underscores 
the therapeutic potential of HMGB1-inactivating strategies in 
treatment of inflammatory disorders of the nasal mucosa. Several 
compounds have been proposed as potential remedies that are 
able to counteract the proinflammatory role of HMGB1. These 
are, for instance, the HMGB1 receptor antagonist HMGB1-BoxA, 
the anti-HMGB1 antibodies, or the HMGB1-scavenging com-
pounds thrombomodulin, polymyxin B, and GLT. To the best of 
our knowledge, GLT is the sole compound used to inhibit HMGB1 
signalling in the clinic due to its anti-inflammatory properties (see 
http://www.minophagen.co.jp). In this respect, the nasal formula-
tion Narivent is a recently developed GLT-containing medical de-
vice used to treat inflammation of the nasal mucosa [15]. There-
fore, on one hand, the use of GLT-containing formulations may 
help unravel the pathogenetic role of HMGB1 in rhinitis-related 
disorders, and on the other hand, it may represent innovative tools 
for the treatment of upper airway inflammation.
 We originally reported that among human leukocytes, eosino-
phils are the major source of extracellular HMGB1. Of note, we 
reasoned that the presence of HMGB1 in leukocyte culture me-
dia is not due to cell death-dependent passive release because 
during the early incubation times we performed evaluation of 
entrance of propidium Iodide (a prototypical marker of cell 
death) which showed no signs of cell demise (data not shown). 
Evidence that eosinophils show higher HMGB1 release among 
white blood cells is in keeping with the survival-promoting effect 
of HMGB1 on eosinophils [18]. Also, the finding that GLT selec-
tively induced eosinophil death indicates that GLT is not cyto-
toxic per se. It also suggests that eosinophils are the only leuko-
cyte subtype that needs HMGB1 for survival. To the best of our 
knowledge, this is the first evidence suggesting that signalling 
from extracellular HMGB1 is selectively required by eosinophils 
to avoid cell death. Why HMGB1 signalling is dispensable for 
survival of the other leukocyte population is currently not 
known. In this regard, it will be interesting to decipher the mech-
anisms underpinning the survival-promoting effect of HMGB1 in 
eosinophils and to investigate whether/why these mechanisms 
do not operate in other leukocytes. As a final note, we reasoned 
that the reduced HMGB1 levels in nasal fluids of patients treated 
with Narivent can be attributed to the ability of GLT to selec-
tively kill eosinophils, which are a major source of extracellular 
HMGB1. Overall, this study improves our understanding of the 
effects of HMGB1 on human leukocytes, and corroborates the 
therapeutic potential and safety profile of GLT in topical treat-
ment of rhinitis.
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Fig. 2. High mobility group protein box 1 (HMGB1) release and effect of glycyrrhizin on survival of different cultured leukocytes. (A) HMGB1 lev-
els in the media of different human leukocyte types purified from peripheral blood and cultured for 12 hours. (B) Effect of GLT on cell survival of 
different human leukocyte types purified from peripheral blood and cultured for 24 hours. Columns represent the mean±standard error of the 
mean of at least three experiments conducted in duplicate. **P<0.01. ***P<0.001; analysis of variance plus Tukey post hoc test. PI, propidium 
Iodide.
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